Vascular Biogenics (VBLT) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VBLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VBLT, but not buy additional shares or sell existing shares.
View VBLT analyst ratings or view top-rated stocks.

3 brokers have issued 12 month target prices for Vascular Biogenics' stock. Their VBLT share price forecasts range from $5.50 to $5.50. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 2,520.3% from the stock's current price.
View analysts price targets for VBLT or view top-rated stocks among Wall Street analysts.

Vascular Biogenics' stock was trading at $0.12 at the beginning of the year. Since then, VBLT stock has increased by 74.9% and is now trading at $0.2099.
View the best growth stocks for 2023 here.

Vascular Biogenics saw a increase in short interest in May. As of May 15th, there was short interest totaling 812,500 shares, an increase of 117.1% from the April 30th total of 374,200 shares. Based on an average daily volume of 4,180,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.5% of the shares of the company are short sold.
View Vascular Biogenics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our VBLT earnings forecast.

Vascular Biogenics Ltd. (NASDAQ:VBLT) announced its quarterly earnings data on Tuesday, March, 14th. The biopharmaceutical company reported ($0.05) EPS for the quarter. Vascular Biogenics had a negative net margin of 4,465.93% and a negative trailing twelve-month return on equity of 96.11%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

Vascular Biogenics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Group One Trading L.P. (0.00%), Simplex Trading LLC (0.00%) and Belvedere Trading LLC (0.00%).

Shares of VBLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VBLT stock can currently be purchased for approximately $0.21.

Vascular Biogenics (NASDAQ:VBLT) has a market capitalization of $14.64 million and generates $660,000.00 in revenue each year. The biopharmaceutical company earns $-32,300,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis.

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The official website for the company is www.vblrx.com. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at ir@vblrx.com, or via fax at 972-8993-5001.